28,580 Alzheimer's and dementia studies in plain English, each scored out of 100.
Diabetes and prediabetes accelerate cognitive decline and might predict microvascular lesions among dementia-free older adults. 4 key findings →
Design: longitudinal study Participants: 2,746 Evidence: moderate
Full summary, score breakdown and related studies → Original source
Incident AF was associated with an increased risk of dementia, independent of clinical stroke in an elderly population. 5 key findings →
Design: longitudinal study Participants: 435 Evidence: moderate
Full summary, score breakdown and related studies → Original source
IR is related to subsequent poorer cognitive performance and greater cognitive decline among patients with cardiovascular disease with and without diabetes. 3 key findings →
Participants: 558 Evidence: low
Full summary, score breakdown and related studies → Original source
Dementia is a major contributor to dependence and disability in older people, with aging societies characterized by growing numbers of people living with the condition. 5 key findings →
Design: systematic review Evidence: high
Full summary, score breakdown and related studies → Original source
Modifiable risk factors identified in this study, especially those with high-level evidence, should be considered in dementia prevention. 2 key findings →
Design: meta-analysis Evidence: high
Full summary, score breakdown and related studies → Original source
A reduction in the incidence of smoking will likely reduce the future prevalence of AD. 5 key findings →
Design: systematic review Evidence: high
Full summary, score breakdown and related studies → Original source
The findings of this study suggest an increased risk of dementia among individuals with TBI. 3 key findings →
Design: cohort study Participants: 44,925 Evidence: moderate
Full summary, score breakdown and related studies → Original source
Our results support an association between the use of ADT in the treatment of prostate cancer and an increased risk of Alzheimer's disease in a general population cohort. 4 key findings →
Design: retrospective cohort Participants: 16,888 Evidence: moderate
Full summary, score breakdown and related studies → Original source
Androgen deprivation therapy in the treatment of prostate cancer may be associated with an increased risk of dementia. 5 key findings →
Design: cohort study Participants: 9,455 Evidence: moderate
Full summary, score breakdown and related studies → Original source
Dialysis modality is associated with incident dementia in a cohort of older ESRD patients. 4 key findings →
Design: cohort study Participants: 121,623 Evidence: moderate
Full summary, score breakdown and related studies → Original source
Pioglitazone is a time- and dose-dependent protective factor against dementia in patients with diabetes. 2 key findings →
Design: cohort study Participants: 6,401 Evidence: moderate
Full summary, score breakdown and related studies → Original source
Dementia is among various diseases affecting the elderly, who is also at a high risk for fractures. 3 key findings →
Design: cohort study Participants: 66,797 Evidence: moderate
Full summary, score breakdown and related studies → Original source
Deintensification of treatment regimens occurred in less than one-half of potentially overtreated Veterans and was more strongly associated with low HbA1c values and use of medications with high risk for hypoglycemia, rather than other resident characteristics. 5 key findings →
Design: cohort study Participants: 3,056 Evidence: moderate
Full summary, score breakdown and related studies → Original source
Brief Report15 September 1991Postmenopausal Estrogen and Prevention BiasElizabeth Barrett-Connor, MDElizabeth Barrett-Connor, MDAuthor, Article, and Disclosure Informationhttps://doi.org/10.7326/0003-4819-115-6-455 SectionsAboutPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail ExcerptIn the last decade many investigators reported that postmenopausal women taking estrogen were at reduced risk for cardiovascular disease compared with women not taking estrogen (1). 3 key findings →
Design: systematic review Evidence: high
Full summary, score breakdown and related studies → Original source
To examine the relationship between smoking and Alzheimer's disease (AD) after controlling for study design, quality, secular trend, and tobacco industry affiliation of the authors, electronic databases were searched; 43 individual studies met the inclusion criteria. 4 key findings →
Design: meta-analysis Evidence: high
Full summary, score breakdown and related studies → Original source
Numerous studies have found associations between characteristics of urban environments and risk factors for dementia and cognitive decline, such as physical inactivity and obesity. 1 key finding →
Design: cohort study Participants: 1,800 Evidence: moderate
Full summary, score breakdown and related studies → Original source
This expert commission synthesized decades of population-level (observational) research to estimate how much dementia risk could theoretically be reduced by addressing 14 modifiable risk factors across life, from childhood education to late-life social isolation. 3 key findings →
Design: systematic-review Evidence: moderate
Full summary, score breakdown and related studies → Original source
Using nearly 8,000 British civil servants followed for up to 25 years (the Whitehall II study), this study found that people who slept 6 hours or less per night in their 50s and 60s had a higher later risk of dementia than those sleeping about 7 hours, even after accounting for other health and social factors. 4 key findings →
Design: cohort Participants: 7,959 Evidence: moderate
Full summary, score breakdown and related studies → Original source
This prospective study followed 392 older spousal caregivers and 427 non-caregivers for an average of 4.5 years. 3 key findings →
Design: cohort Participants: 819 Evidence: high
Full summary, score breakdown and related studies → Original source
Among eligible participants (n = 705,061), 264,294 individuals (37.5% of eligible participants) initiated any statin during 2001-2010 ("initiators"), of whom 249,613 (94.4%) were matched with 255,937 unique noninitiators to create the analytic sample (322,358 unique participants; mean age at baseline = 67.4 years; 55.1% female). 3 key findings →
Design: cohort Participants: 322,358 Evidence: high
Full summary, score breakdown and related studies → Original source Free full text
Our findings suggest that statins might be associated with a lower risk of incident AD among individuals with the APOE ε4 allele. 5 key findings →
Design: cohort Participants: 4,807 Evidence: early
Full summary, score breakdown and related studies → Original source Free full text
In this cohort study, high adherence to a flavonoid-rich diet score was associated with a lower risk of dementia, with reductions more pronounced in individuals with a high genetic risk, hypertension, and depressive symptoms. 5 key findings →
Design: cohort Participants: 121,986 Evidence: moderate
Full summary, score breakdown and related studies → Original source Free full text
After a median follow-up of 6.3 years, 678 individuals were diagnosed with dementia. 4 key findings →
Design: cohort Participants: 84,854 Evidence: moderate
Full summary, score breakdown and related studies → Original source Free full text
Cognitive reserve (CR) may reduce the risk of dementia. 5 key findings →
Design: meta-analysis Evidence: moderate
Full summary, score breakdown and related studies → Original source Free full text
A substantial proportion of the relationship between education and dementia was mediated through mid-life vascular risk factors. 2 key findings →
Design: cohort Participants: 13,368 Evidence: moderate
Full summary, score breakdown and related studies → Original source Free full text
10 of the 3,290 studies in this tag that have a study page, picked by a fixed rule (a hash of each study's address), not by score or date; each page of this list shows a different 10. The same 10 appear here every time.
Free full text links and the Full text may need a subscription label come from Unpaywall, Europe PMC and OpenAlex records of free copies, checked 10 Oct 2026. A study with neither is unknown, not paywalled. Show only studies that are free to read
This is alzhub's own score. It is not an official metric, not an impact factor, and no journal, publisher or ranking body endorses it. We built it so that a reader who is not a scientist can tell a landmark trial from a conference abstract without having to already know the difference. Every point comes from one of 20 components, all of them printed on the study itself, so you can disagree with our arithmetic rather than having to trust the total.
Journals are placed in ordered tiers, never given a numeric impact factor — we could not verify current impact factors from a source we control, and an invented one would be worse than none. Tier 1 is the top-tier general journals (NEJM, The Lancet, JAMA, Nature, Science, Nature Medicine); tier 2 is the leading specialty journals; tier 3 is every other peer-reviewed journal. A separate part scores how much the journal's own papers are cited, which tells the tier-3 journals apart.
Two rules we don't bend. First, we never fill in a missing value: if a record does not state a sample size or a design, that component scores zero, and if we simply have no data for a part, such as a citation count, that part is left out and the study is scored on the parts we could check. The study card says which. Second, anything that is not a peer-reviewed article is capped at 16/100 and carries a warning chip — so a conference abstract or a company press release can never outrank a peer-reviewed paper, no matter how good it looks.
We rank a rigorous null result — a good trial showing that something does not work — above an early positive finding. Someone deciding whether to buy a supplement is served by that, and the rigour is already counted by the design and journal components.
The score is computed from the published data alone and is reproducible: the same file always yields the same numbers.
See the whole rubric drawn out → — four charts covering all 28,580 studies: how the scores are spread and where the cap bites, which of the 20 components the library is strong and weak on, which subjects rest on stronger evidence, and what kinds of study each subject is actually built from.
This is a large sample of the Alzheimer's literature, not an exhaustive index of it. It holds 28,580 records, built mostly from automated pulls of Europe PMC (62.2% of the library) and OpenAlex (17.8%), plus smaller pulls from PubMed, Crossref and medRxiv. If a study, a drug, or a finding isn't here, that is not evidence it doesn't exist in the literature — it may simply not have been pulled in yet.
1,034 records (3.6% of the library) are not peer-reviewed — 962 of those are preprints posted before any journal review, and the rest are conference abstracts, regulatory notices and reports. Every study card on this page states its status plainly, and the score above is capped for anything that isn't a peer-reviewed article.
See the full, machine-readable breakdown of this library's coverage →